Literature DB >> 12941922

Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys.

Ramu A Subbramanian1, Marcelo J Kuroda, William A Charini, Dan H Barouch, Cristina Costantino, Sampa Santra, Jörn E Schmitz, Kristi L Martin, Michelle A Lifton, Darci A Gorgone, John W Shiver, Norman L Letvin.   

Abstract

In an effort to develop an AIDS vaccine that elicits high-frequency cytotoxic-T-lymphocyte (CTL) responses with specificity for a diversity of viral epitopes, we explored two prototype multiepitope plasmid DNA vaccines in the simian-human immunodeficiency virus/rhesus monkey model to determine their efficiency in priming for such immune responses. While a simple multiepitope vaccine construct demonstrated limited immunogenicity in monkeys, this same multiepitope genetic sequence inserted into an immunogenic simian immunodeficiency virus gag DNA vaccine elicited high-frequency CTL responses specific for all of the epitopes included in the vaccine. Both multiepitope vaccine prototypes primed for robust epitope-specific CTL responses that developed following boosting with recombinant modified vaccinia virus Ankara vaccines expressing complete viral proteins. The natural hierarchy of immunodominance for these epitopes was clearly evident in the boosted monkeys. These studies suggest that multiepitope plasmid DNA vaccine-based prime-boost regimens can efficiently prime for CTL responses of increased breadth and magnitude, although they do not overcome predicted hierarchies of immunodominance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941922      PMCID: PMC224609          DOI: 10.1128/jvi.77.18.10113-10118.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

Review 2.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  Rama Rao Amara; Francois Villinger; John D Altman; Shari L Lydy; Shawn P O'Neil; Silvija I Staprans; David C Montefiori; Yan Xu; James G Herndon; Linda S Wyatt; Maria Angelito Candido; Natalia L Kozyr; Patricia L Earl; James M Smith; Hak-Ling Ma; Bennett D Grimm; Michael L Hulsey; Harold M McClure; Janet M McNicholl; Bernard Moss; Harriet L Robinson
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

3.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

4.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

5.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

Authors:  David H O'Connor; Todd M Allen; Thorsten U Vogel; Peicheng Jing; Ivan P DeSouza; Elizabeth Dodds; Edward J Dunphy; Cheri Melsaether; Bianca Mothé; Hiroshi Yamamoto; Helen Horton; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

7.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.

Authors:  T Hanke; R V Samuel; T J Blanchard; V C Neumann; T M Allen; J E Boyson; S A Sharpe; N Cook; G L Smith; D I Watkins; M P Cranage; A J McMichael
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

10.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

View more
  15 in total

1.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Contribution of T-cell receptor repertoire breadth to the dominance of epitope-specific CD8+ T-lymphocyte responses.

Authors:  Edwin R Manuel; William A Charini; Pritha Sen; Fred W Peyerl; Marcelo J Kuroda; Jörn E Schmitz; Patrick Autissier; Dennis A Sheeter; Bruce E Torbett; Norman L Letvin
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.

Authors:  Jorge A Tavel; Julie E Martin; Grace G Kelly; Mary E Enama; Jean M Shen; Phillip L Gomez; Charla A Andrews; Richard A Koup; Robert T Bailer; Judy A Stein; Mario Roederer; Gary J Nabel; Barney S Graham
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

4.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Authors:  Geoffrey J Gorse; Mark J Newman; Allan deCamp; Christine Mhorag Hay; Stephen C De Rosa; Elizabeth Noonan; Brian D Livingston; Jonathan D Fuchs; Spyros A Kalams; Farah L Cassis-Ghavami
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

5.  Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity.

Authors:  Alessandro Sette; John Sidney; Huynh-Hoa Bui; Marie-France del Guercio; Jeff Alexander; John Loffredo; David I Watkins; Bianca R Mothé
Journal:  Immunogenetics       Date:  2005-03-04       Impact factor: 2.846

6.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

7.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

8.  Evaluation of a quantitative real-time PCR assay to measure HIV-specific mucosal CD8+ T cell responses in the cervix.

Authors:  Duncan Chege; Yijie Chai; Sanja Huibner; Lyle McKinnon; Charles Wachihi; Makubo Kimani; Walter Jaoko; Joshua Kimani; T Blake Ball; Francis A Plummer; Rupert Kaul; Anuradha Rebbapragada
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

9.  Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.

Authors:  Pritha Sen; William A Charini; Ramu A Subbramanian; Edwin R Manuel; Marcelo J Kuroda; Patrick A Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

Review 10.  Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.

Authors:  Devon J Shedlock; Guido Silvestri; David B Weiner
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.